Ultragenyx Pharmaceutical Inc. $RARE Shares Bought by Privium Fund Management B.V.

Key Points

• Privium Fund Management boosted its stake in Ultragenyx by 23.4% to 357,502 shares (about $8.22M), and institutional investors now own 97.67% of the stock, signaling heavy institutional interest and potential trading stability from large holders.
• Ultragenyx missed Q1 estimates with EPS of -$1.84 (vs. ~-$1.50 expected) and revenue of $136M (vs. $158M expected); product sales included Crysvita $93M and Dojolvi $18M, and FY-2026 revenue guidance of $730–$760M roughly tracks Street expectations.
• Analyst opinions are mixed—average target ≈ $60.76 with notable downgrades (Goldman to $25) and upgrades (Truist strong-buy)—while insiders have sold ~111,178 shares in the last 90 days, contributing to near-term volatility risk.

Privium Fund Management B.V. grew its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 23.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 357,502 shares of the biopharmaceutical company's stock after acquiring an additional 67,698 shares during the quarter. Ultragenyx Pharmaceutical comprises about 1.5% of Privium Fund Management B.V.'s holdings, making the stock its 20th largest position. Privium Fund Management B.V. owned 0.37% of Ultragenyx Pharmaceutical worth $8,223,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 10,263,815 shares of the biopharmaceutical company's stock valued at $236,068,000 after acquiring an additional 131,087 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 614.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company's stock valued at $65,205,000 after acquiring an additional 1,864,164 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Ultragenyx Pharmaceutical by 3.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,945,129 shares of the biopharmaceutical company's stock valued at $58,509,000 after acquiring an additional 73,309 shares during the last quarter. Aberdeen Group plc increased its stake in shares of Ultragenyx Pharmaceutical by 51.0% during the 4th quarter. Aberdeen Group plc now owns 1,469,951 shares of the biopharmaceutical company's stock valued at $33,809,000 after acquiring an additional 496,295 shares during the last quarter. Finally, Alliancebernstein L.P. increased its stake in shares of Ultragenyx Pharmaceutical by 0.6% during the 2nd quarter. Alliancebernstein L.P. now owns 1,255,203 shares of the biopharmaceutical company's stock valued at $45,639,000 after acquiring an additional 7,823 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on RARE shares. The Goldman Sachs Group downgraded shares of Ultragenyx Pharmaceutical from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $61.00 to $25.00 in a research note on Tuesday, March 24th. Canaccord Genuity Group dropped their price objective on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a "buy" rating for the company in a research note on Wednesday, February 18th. Morgan Stanley boosted their target price on Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the stock an "overweight" rating in a report on Thursday, April 16th. Wall Street Zen upgraded Ultragenyx Pharmaceutical from a "sell" rating to a "hold" rating in a report on Sunday. Finally, Truist Financial upgraded Ultragenyx Pharmaceutical to a "strong-buy" rating in a report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $60.76.

Ultragenyx Pharmaceutical Stock Up 0.8%

NASDAQ RARE opened at $25.01 on Wednesday. The stock has a market cap of $2.46 billion, a PE ratio of -4.28 and a beta of 0.39. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $18.29 and a fifty-two week high of $42.37. The business has a 50 day moving average price of $22.55 and a two-hundred day moving average price of $26.90.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share for the quarter, missing analysts' consensus estimates of ($1.50) by ($0.34). The company had revenue of $136.00 million during the quarter, compared to analysts' expectations of $158.38 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The firm's revenue was down 2.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.57) EPS. Sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -4.49 EPS for the current fiscal year.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Crysvita and Dojolvi product sales provide commercial ballast — Q1 product revenues included Crysvita $93M and Dojolvi $18M, showing underlying commercial traction even as total revenue declined. GlobeNewswire: Q1 Results
• Positive Sentiment: Some analysts remain bullish — a recent published price target of $61.18 signals continued upside expectations from parts of the street, which can support buying interest over the medium term. Analyst Price Target
• Neutral Sentiment: FY-2026 revenue guidance given as $730M–$760M (consensus ~$747M) — the range straddles Street expectations, so the top-line outlook is roughly in line with consensus but leaves EPS guidance unclear in public notes. This tempers but does not resolve near-term earnings concerns. Guidance in Press Release
• Neutral Sentiment: Large institutional holdings and recent stake increases from firms like Vanguard and State Street indicate continued institutional interest that may stabilize trading. MarketBeat: Institutional Holdings
• Negative Sentiment: Q1 EPS missed materially: reported loss per share $1.84 vs. consensus ≈ $1.50–$1.55; revenue fell ~2.2% YoY to $136M, underscoring near-term profitability and growth concerns. These misses are the primary negative driver. Zacks: Q1 Loss, Miss
• Negative Sentiment: Insider selling by the CFO (multiple recent sales, latest ~4,683 shares) may be viewed negatively by some investors as a signal of reduced insider conviction or portfolio diversification. SEC Filing: Insider Sale
• Negative Sentiment: Broader sell-side repositioning (e.g., past Goldman downgrade and mixed analyst actions) increases short-term volatility risk as investors digest the earnings gap and guidance nuance. MarketBeat: Analyst Notes

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 8,409 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.70, for a total transaction of $190,884.30. Following the completion of the transaction, the chief financial officer directly owned 86,669 shares in the company, valued at approximately $1,967,386.30. This represents a 8.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Karah Herdman Parschauer sold 8,135 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $185,478.00. Following the transaction, the executive vice president owned 76,346 shares of the company's stock, valued at approximately $1,740,688.80. This trade represents a 9.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 111,178 shares of company stock worth $2,534,628 over the last 90 days. 5.20% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.